

Xavier Delavenne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1021331/publications.pdf>

Version: 2024-02-01

74
papers

1,648
citations

304743

22
h-index

345221

36
g-index

80
all docs

80
docs citations

80
times ranked

2339
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. <i>Thrombosis and Haemostasis</i> , 2014, 112, 240-248.	3.4	111
2	Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 273-283.	3.8	111
3	Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. <i>Pharmacological Research</i> , 2017, 118, 19-32.	7.1	102
4	Prevalence of poor biological response to clopidogrel. <i>Thrombosis and Haemostasis</i> , 2012, 107, 494-506.	3.4	81
5	Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2227-2229.	5.8	80
6	A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 107-113.	2.4	60
7	UPLC MS/MS assay for routine quantification of dabigatran – A direct thrombin inhibitor – In human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 58, 152-156.	2.8	58
8	Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 78-79, 150-153.	2.8	49
9	In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 183-191.	1.6	42
10	Pharmacological characterization of the 3D MucilAir [®] nasal model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 139, 186-196.	4.3	39
11	Assessment of HBEC-5i endothelial cell line cultivated in astrocyte conditioned medium as a human blood-brain barrier model for ABC drug transport studies. <i>International Journal of Pharmaceutics</i> , 2018, 551, 281-289.	5.2	38
12	Exposure-Response Relationship of Tranexamic Acid in Cardiac Surgery. <i>Anesthesiology</i> , 2021, 134, 165-178.	2.5	37
13	UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study. <i>Clinica Chimica Acta</i> , 2011, 412, 59-65.	1.1	34
14	Intravenous Tranexamic Acid Bolus plus Infusion Is Not More Effective than a Single Bolus in Primary Hip Arthroplasty. <i>Anesthesiology</i> , 2017, 127, 413-422.	2.5	34
15	In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 604-614.	1.9	31
16	Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. <i>Pharmacological Research</i> , 2017, 118, 33-42.	7.1	31
17	Potential usefulness of activated charcoal (DOAC remove [®]) for dRVVT testing in patients receiving Direct Oral AntiCoagulants. <i>Thrombosis Research</i> , 2019, 184, 86-91.	1.7	30
18	Individualized PK-based prophylaxis in severe haemophilia. <i>Haemophilia</i> , 2018, 24, 3-17.	2.1	28

#	ARTICLE	IF	CITATIONS
19	Effect of Activated Charcoal on Rivaroxaban Complex Absorption. <i>Clinical Pharmacokinetics</i> , 2017, 56, 793-801.	3.5	27
20	A Pharmacokinetic-Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy. <i>Clinical Pharmacokinetics</i> , 2012, 51, 41-53.	3.5	26
21	Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study. <i>Thrombosis Research</i> , 2017, 158, 126-133.	1.7	26
22	Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1670-1682.	3.8	24
23	Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 13-24.	1.6	23
24	Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite. <i>Journal of Separation Science</i> , 2010, 33, 1968-1972.	2.5	21
25	In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 519-525.	2.5	21
26	Is tranexamic acid exposure related to blood loss in hip arthroplasty? A pharmacokinetic-pharmacodynamic study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 310-319.	2.4	21
27	Investigation of drug-drug interactions between clopidogrel and fluoxetine. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 683-689.	1.9	20
28	Inflammation Induces Changes in the Functional Expression of P-gp, BCRP, and MRP2: An Overview of Different Models and Consequences for Drug Disposition. <i>Pharmaceutics</i> , 2021, 13, 1544.	4.5	20
29	Antipsychotics: A Real or Confounding Risk Factor for Venous Thromboembolism?. <i>Pharmacopsychiatry</i> , 2013, 46, 36-37.	3.3	19
30	Quantification of total and unbound tranexamic acid in human plasma by ultrafiltration liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic analysis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 91, 32-36.	2.8	18
31	Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension. <i>Respiration</i> , 2016, 91, 307-315.	2.6	18
32	Pharmacokinetic/pharmacodynamic model for unfractionated heparin dosing during cardiopulmonary bypass. <i>British Journal of Anaesthesia</i> , 2017, 118, 705-712.	3.4	18
33	In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 109-119.	1.9	18
34	Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice. <i>Thrombosis and Haemostasis</i> , 2010, 104, 252-260.	3.4	17
35	Pharmacological Characterization of the RPMI 2650 Model as a Relevant Tool for Assessing the Permeability of Intranasal Drugs. <i>Molecular Pharmaceutics</i> , 2018, 15, 2246-2256.	4.6	16
36	Direct oral anticoagulants are associated with limited damage of endothelial cells of the blood-brain barrier mediated by the thrombin/PAR-1 pathway. <i>Brain Research</i> , 2019, 1719, 57-63.	2.2	16

#	ARTICLE	IF	CITATIONS
37	Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?. <i>Blood Reviews</i> , 2019, 37, 100579.	5.7	16
38	A new paradigm for personalized prophylaxis for patients with severe haemophilia A. <i>Haemophilia</i> , 2020, 26, 228-235.	2.1	16
39	Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1403-1410.	1.9	15
40	Population pharmacokinetic model of free and total ropivacaine after transversus abdominis plane nerve block in patients undergoing liver resection. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 67-74.	2.4	15
41	Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience. <i>Transplantation</i> , 2020, 104, 2625-2631.	1.0	15
42	A new Strategy to Improve Drug Delivery to the Maxillary Sinuses: The Frequency Sweep Acoustic Airflow. <i>Pharmaceutical Research</i> , 2016, 33, 1074-1084.	3.5	14
43	Pharmacokinetics for haemophilia treaters: Meaning of PK parameters, interpretation pitfalls, and use in the clinic. <i>Thrombosis Research</i> , 2020, 192, 52-60.	1.7	13
44	Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. <i>Thrombosis Research</i> , 2021, 205, 120-127.	1.7	13
45	Investigation of PKâ€‘PD drugâ€‘drug interaction between acenocoumarol and amoxicillin plus clavulanic acid. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 127-135.	1.9	12
46	Glomerular filtration drug injury: In vitro evaluation of functional and morphological podocyte perturbations. <i>Experimental Cell Research</i> , 2017, 361, 300-307.	2.6	12
47	Predicting the dose of vancomycin in ICU patients receiving different types of RRT therapy: a modelâ€‘based metaâ€‘analytic approach. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1215-1226.	2.4	12
48	Dose tailoring of human cell lineâ€‘derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 771-781.	2.4	11
49	Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests?. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2334-2338.	3.8	10
50	Antithrombotics in pulmonary hypertension: more work needed before we turn to newer agents!. <i>European Respiratory Journal</i> , 2013, 41, 775-777.	6.7	10
51	Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 199-201.	2.9	8
52	Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A timeâ€‘toâ€‘event analysis. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2242-2251.	2.4	7
53	Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drugâ€‘drug interaction mediated by Pâ€‘glycoprotein. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 860-868.	1.9	7
54	HPLC MS/MS method for quantification of meprobamate in human plasma: Application to 24/7 clinical toxicology. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 215-218.	2.3	6

#	ARTICLE	IF	CITATIONS
55	Immunosuppression by a subconjunctival implant releasing dexamethasone in a rabbit model of penetrating keratoplasty. <i>British Journal of Ophthalmology</i> , 2018, 102, 692-699.	3.9	6
56	Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 148, 27-37.	4.3	6
57	A SAEM algorithm for fused lasso penalized NonLinear Mixed Effect Models: Application to group comparison in pharmacokinetics. <i>Computational Statistics and Data Analysis</i> , 2016, 95, 207-221.	1.2	5
58	The expected characteristics of an in vitro human Blood Brain Barrier model derived from cell lines, for studying how ABC transporters influence drug permeability. <i>Journal of Drug Delivery Science and Technology</i> , 2018, 45, 159-167.	3.0	5
59	Population pharmacokinetic model of cefazolin in total hip arthroplasty. <i>Scientific Reports</i> , 2021, 11, 19763.	3.3	5
60	Accidental apixaban intoxication in a 23-month-old child: a case report. <i>BMC Pediatrics</i> , 2020, 20, 546.	1.7	4
61	Is the human model RPTEC/TERT1 a relevant model for assessing renal drug efflux?. <i>Fundamental and Clinical Pharmacology</i> , 2020, 35, 732-743.	1.9	4
62	Severe Inflammation, Acute Kidney Injury, and Drug-Drug Interaction: Triple Penalty for Prolonged Elimination of Apixaban in Patients With Coronavirus Disease 2019: A Grand Round. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 455-458.	2.0	4
63	Effects of heparin and derivatives on podocytes: An in vitro functional and morphological evaluation. <i>Journal of Cellular Physiology</i> , 2019, 234, 15438-15449.	4.1	3
64	In Vitro Evaluation of P-gp-Mediated Drug-Drug Interactions Using the RPTEC/TERT1 Human Renal Cell Model. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 223-233.	1.6	3
65	Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis. <i>Haemophilia</i> , 2022, , .	2.1	3
66	PK evaluation of fondaparinux sodium for the treatment of thrombosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 269-277.	3.3	2
67	Pharmacokinetic Model for Cefuroxime Dosing during Cardiac Surgery under Cardiopulmonary Bypass. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	2
68	Pharmacobezoars After Venlafaxine and Oxazepam Overdose: How Pharmacokinetics Could Help?—A Grand Round. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 143-145.	2.0	2
69	Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients. <i>Clinical Nephrology</i> , 2012, 77, 425-431.	0.7	2
70	The impact of advanced age on anticoagulant therapy for acute venous thromboembolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 27-37.	3.3	2
71	Direct oral anticoagulants: Still too early for prime time after pulmonary endarterectomy?. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 758-759.	3.8	1
72	Functional, proteomic and phenotypic in vitro studies evidence podocyte injury after chronic exposure to heparin. <i>Toxicology and Applied Pharmacology</i> , 2021, 429, 115683.	2.8	1

#	ARTICLE	IF	CITATIONS
73	TNF- α and IL-1 β Exposure Modulates the Expression and Functionality of <i>P</i> -Glycoprotein in Intestinal and Renal Barriers. <i>Molecular Pharmaceutics</i> , 2022, 19, 2327-2334.	4.6	1
74	Development of a Bayesian estimation tool to determine the optimal duration of apixaban discontinuation before a high-bleeding risk procedure. <i>Fundamental and Clinical Pharmacology</i> , 2022, ,	1.9	0